Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient

Valerio Carelli, Piero Barboni, Annalisa Zacchini, Rita Mancini, Lucia Monari, Sabina Cevoli, Rocco Liguori, Mariachiara Sensi, Elio Lugaresi, Pasquale Montagna

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We report the clinical and genetic study of a Leber's Hereditary Optic Neuropathy (LHON) patient of North African origin harboring the 14484/ND6 mutation of mtDNA. For over a year we followed the ophthalmological course of this 24-year-old male with LHON treated with idebenone and vitamin B12. Serum lactate after effort was evaluated before, during and after therapy. Muscle biopsy was obtained for morphological study. Homo/heteroplasmy of 14484/ND6 mutation was studied in different tissues. Recovery of visual acuity was documented 6 months after onset and 3 months after therapy was established. Baseline serum lactate was elevated but normalized after 3.5 months of therapy. Muscle biopsy demonstrated only a few fibers with a slightly increased subsarcolemmal SDH activity. Genetic analysis showed homoplasmic 14484/ND6 mutation in all tissues investigated. The clinical phenotype of LHON/14484 in this patient closely resembles that commonly found in European patients. Even if LHON/14484 patients are reported to have a better prognosis for visual recovery, it is possible that the evolution of visual recovery in this patient could have been influenced by therapy as suggested by changes in serum lactate levels. Bioenergetic impairment of skeletal muscle was documented by lactate levels and muscle morphology. The 14484/ND6 mutation behaves as a primary mutation regardless of mtDNA population-specific backgrounds.

Original languageEnglish
Pages (from-to)183-188
Number of pages6
JournalJournal of the Neurological Sciences
Volume160
Issue number2
DOIs
Publication statusPublished - Oct 8 1998

Fingerprint

Leber's Hereditary Optic Atrophy
Lactic Acid
Mutation
Mitochondrial DNA
Muscles
Serum
Biopsy
Hominidae
Therapeutics
Vitamin B 12
Energy Metabolism
Visual Acuity
Skeletal Muscle
Phenotype
Population

Keywords

  • 14484 LHON mutation
  • Idebenone
  • Leber's Hereditary Optic Neuropathy
  • Mitochondria
  • MtDNA haplogroups
  • Visual recovery

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient. / Carelli, Valerio; Barboni, Piero; Zacchini, Annalisa; Mancini, Rita; Monari, Lucia; Cevoli, Sabina; Liguori, Rocco; Sensi, Mariachiara; Lugaresi, Elio; Montagna, Pasquale.

In: Journal of the Neurological Sciences, Vol. 160, No. 2, 08.10.1998, p. 183-188.

Research output: Contribution to journalArticle

Carelli, Valerio ; Barboni, Piero ; Zacchini, Annalisa ; Mancini, Rita ; Monari, Lucia ; Cevoli, Sabina ; Liguori, Rocco ; Sensi, Mariachiara ; Lugaresi, Elio ; Montagna, Pasquale. / Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient. In: Journal of the Neurological Sciences. 1998 ; Vol. 160, No. 2. pp. 183-188.
@article{7f3e2eb8e639431a84d2666cd1989160,
title = "Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient",
abstract = "We report the clinical and genetic study of a Leber's Hereditary Optic Neuropathy (LHON) patient of North African origin harboring the 14484/ND6 mutation of mtDNA. For over a year we followed the ophthalmological course of this 24-year-old male with LHON treated with idebenone and vitamin B12. Serum lactate after effort was evaluated before, during and after therapy. Muscle biopsy was obtained for morphological study. Homo/heteroplasmy of 14484/ND6 mutation was studied in different tissues. Recovery of visual acuity was documented 6 months after onset and 3 months after therapy was established. Baseline serum lactate was elevated but normalized after 3.5 months of therapy. Muscle biopsy demonstrated only a few fibers with a slightly increased subsarcolemmal SDH activity. Genetic analysis showed homoplasmic 14484/ND6 mutation in all tissues investigated. The clinical phenotype of LHON/14484 in this patient closely resembles that commonly found in European patients. Even if LHON/14484 patients are reported to have a better prognosis for visual recovery, it is possible that the evolution of visual recovery in this patient could have been influenced by therapy as suggested by changes in serum lactate levels. Bioenergetic impairment of skeletal muscle was documented by lactate levels and muscle morphology. The 14484/ND6 mutation behaves as a primary mutation regardless of mtDNA population-specific backgrounds.",
keywords = "14484 LHON mutation, Idebenone, Leber's Hereditary Optic Neuropathy, Mitochondria, MtDNA haplogroups, Visual recovery",
author = "Valerio Carelli and Piero Barboni and Annalisa Zacchini and Rita Mancini and Lucia Monari and Sabina Cevoli and Rocco Liguori and Mariachiara Sensi and Elio Lugaresi and Pasquale Montagna",
year = "1998",
month = "10",
day = "8",
doi = "10.1016/S0022-510X(98)00239-1",
language = "English",
volume = "160",
pages = "183--188",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient

AU - Carelli, Valerio

AU - Barboni, Piero

AU - Zacchini, Annalisa

AU - Mancini, Rita

AU - Monari, Lucia

AU - Cevoli, Sabina

AU - Liguori, Rocco

AU - Sensi, Mariachiara

AU - Lugaresi, Elio

AU - Montagna, Pasquale

PY - 1998/10/8

Y1 - 1998/10/8

N2 - We report the clinical and genetic study of a Leber's Hereditary Optic Neuropathy (LHON) patient of North African origin harboring the 14484/ND6 mutation of mtDNA. For over a year we followed the ophthalmological course of this 24-year-old male with LHON treated with idebenone and vitamin B12. Serum lactate after effort was evaluated before, during and after therapy. Muscle biopsy was obtained for morphological study. Homo/heteroplasmy of 14484/ND6 mutation was studied in different tissues. Recovery of visual acuity was documented 6 months after onset and 3 months after therapy was established. Baseline serum lactate was elevated but normalized after 3.5 months of therapy. Muscle biopsy demonstrated only a few fibers with a slightly increased subsarcolemmal SDH activity. Genetic analysis showed homoplasmic 14484/ND6 mutation in all tissues investigated. The clinical phenotype of LHON/14484 in this patient closely resembles that commonly found in European patients. Even if LHON/14484 patients are reported to have a better prognosis for visual recovery, it is possible that the evolution of visual recovery in this patient could have been influenced by therapy as suggested by changes in serum lactate levels. Bioenergetic impairment of skeletal muscle was documented by lactate levels and muscle morphology. The 14484/ND6 mutation behaves as a primary mutation regardless of mtDNA population-specific backgrounds.

AB - We report the clinical and genetic study of a Leber's Hereditary Optic Neuropathy (LHON) patient of North African origin harboring the 14484/ND6 mutation of mtDNA. For over a year we followed the ophthalmological course of this 24-year-old male with LHON treated with idebenone and vitamin B12. Serum lactate after effort was evaluated before, during and after therapy. Muscle biopsy was obtained for morphological study. Homo/heteroplasmy of 14484/ND6 mutation was studied in different tissues. Recovery of visual acuity was documented 6 months after onset and 3 months after therapy was established. Baseline serum lactate was elevated but normalized after 3.5 months of therapy. Muscle biopsy demonstrated only a few fibers with a slightly increased subsarcolemmal SDH activity. Genetic analysis showed homoplasmic 14484/ND6 mutation in all tissues investigated. The clinical phenotype of LHON/14484 in this patient closely resembles that commonly found in European patients. Even if LHON/14484 patients are reported to have a better prognosis for visual recovery, it is possible that the evolution of visual recovery in this patient could have been influenced by therapy as suggested by changes in serum lactate levels. Bioenergetic impairment of skeletal muscle was documented by lactate levels and muscle morphology. The 14484/ND6 mutation behaves as a primary mutation regardless of mtDNA population-specific backgrounds.

KW - 14484 LHON mutation

KW - Idebenone

KW - Leber's Hereditary Optic Neuropathy

KW - Mitochondria

KW - MtDNA haplogroups

KW - Visual recovery

UR - http://www.scopus.com/inward/record.url?scp=0032497575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032497575&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(98)00239-1

DO - 10.1016/S0022-510X(98)00239-1

M3 - Article

VL - 160

SP - 183

EP - 188

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 2

ER -